BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 21949984)

  • 1. Federal pre-emption under the Food, Drug & Cosmetic Act from Medtronic, Inc. v. Lohr; Pliva. Inc. v. Mensing.
    Ball FR
    Health Care Law Mon; 2011 Sep; 2011(9):2-8. PubMed ID: 21949984
    [No Abstract]   [Full Text] [Related]  

  • 2. Premarket approval and federal preemption of product liability claims in the wake of Medtronic, Inc. v. Lohr.
    Jarcho DG
    Food Drug Law J; 1996; 51(4):613-8. PubMed ID: 11797730
    [No Abstract]   [Full Text] [Related]  

  • 3. Medical device preemption after Medtronic, Inc. v. Lohr.
    Neraas MB
    Food Drug Law J; 1996; 51(4):619-29. PubMed ID: 11797731
    [No Abstract]   [Full Text] [Related]  

  • 4. License to maim: federal pre-emption and the Medical Device Amendments of 1976.
    Petrella ME
    Health Matrix Clevel; 1996; 6(2):349-89. PubMed ID: 10178392
    [No Abstract]   [Full Text] [Related]  

  • 5. Federal preemption of common law tort awards by the Federal Food, Drug, and Cosmetic Act.
    Carrier MK
    Food Drug Law J; 1996; 51(4):509-611. PubMed ID: 11797729
    [No Abstract]   [Full Text] [Related]  

  • 6. Riegel v. Medtronic, Inc.: revisiting pre-emption for medical devices.
    Patsner B
    J Law Med Ethics; 2009; 37(2):305-17. PubMed ID: 19493075
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact of FDA reform.
    Trunzo J
    Med Device Technol; 2003 Apr; 14(3):36-7. PubMed ID: 12789699
    [TBL] [Abstract][Full Text] [Related]  

  • 8. King v. Collagen Corporation: FDA approval insulates medical device manufacturers from state common law liability.
    Kronenberg AW
    J Contemp Health Law Policy; 1995; 11(2):563-87. PubMed ID: 10184353
    [No Abstract]   [Full Text] [Related]  

  • 9. The FDA defense: a prescription for easing the pain of punitive damage awards in medical products liability cases.
    Marthaler AL
    Spec Law Dig Health Care Law; 1997 Sep; (223):9-45. PubMed ID: 10173273
    [No Abstract]   [Full Text] [Related]  

  • 10. A state of extinction: does Food and Drug Administration approval of a prescription drug label extinguish state claims for inadequate warning?
    O'Reilly JT
    Food Drug Law J; 2003; 58(2):287-97. PubMed ID: 12866560
    [No Abstract]   [Full Text] [Related]  

  • 11. Post-decision diagnosis: medical device preemption alive and mostly well after Medtronic, Inc. v. Lohr.
    Sayler SW; Thomas SM
    Ann Health Law; 1997; 6():185-208. PubMed ID: 10184786
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pin the tail on the other donkey: allocating and avoiding injury losses after drug or device approval.
    O'Reilly JT
    Food Drug Law J; 2007; 62(3):559-72. PubMed ID: 17915397
    [No Abstract]   [Full Text] [Related]  

  • 13. Greater and lesser powers of tort reform: the primary jurisdiction doctrine and state-law claims concerning FDA-approved products.
    Struve CT
    Cornell Law Rev; 2008 Jul; 93(5):1039-74. PubMed ID: 18618970
    [No Abstract]   [Full Text] [Related]  

  • 14. Legal overprotection.
    Friedman JH
    Med Health R I; 2004 Oct; 87(10):294. PubMed ID: 15559378
    [No Abstract]   [Full Text] [Related]  

  • 15. Should preemption apply in a pharmaceutical context? An analysis of the preemption debate and what regulatory compliance statutes contribute to the discussion.
    Surprenant JA
    Fordham Law Rev; 2008 Oct; 77(1):327-63. PubMed ID: 18982554
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PLIVA v. Mensing: generic consumers' unfortunate hand.
    Lee SB
    Yale J Health Policy Law Ethics; 2012; 12(2):209-63. PubMed ID: 23175916
    [No Abstract]   [Full Text] [Related]  

  • 17. The Canadian perspective: trends in drug and medical device class actions in Canada.
    Vernon W
    Food Drug Law J; 2006; 61(3):569-76. PubMed ID: 16989040
    [No Abstract]   [Full Text] [Related]  

  • 18. Pharmaceuticals and Medical Devices: FDA Oversight.
    White RS;
    Issue Brief Health Policy Track Serv; 2016 Dec; 2016():1-74. PubMed ID: 28252887
    [No Abstract]   [Full Text] [Related]  

  • 19. The federal preemption debate in pharmaceutical labeling product liability actions.
    Gross JM; Curry JA
    Tort Trial Insur Pract Law J; 2007; 43(1):35-70. PubMed ID: 18354866
    [No Abstract]   [Full Text] [Related]  

  • 20. Pharmaceuticals and medical devices: FDA oversight. End-of-year issue brief.
    Chaps NA
    Issue Brief Health Policy Track Serv; 2010 Jan; ():1-31. PubMed ID: 20217914
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.